Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

Autophagy is required for glucose homeostasis and lung tumor maintenance.

Karsli-Uzunbas G, Guo JY, Price S, Teng X, Laddha SV, Khor S, Kalaany NY, Jacks T, Chan CS, Rabinowitz JD, White E.

Cancer Discov. 2014 Aug;4(8):914-27. doi: 10.1158/2159-8290.CD-14-0363. Epub 2014 May 29.

2.

Autophagy suppresses progression of K-ras-induced lung tumors to oncocytomas and maintains lipid homeostasis.

Guo JY, Karsli-Uzunbas G, Mathew R, Aisner SC, Kamphorst JJ, Strohecker AM, Chen G, Price S, Lu W, Teng X, Snyder E, Santanam U, Dipaola RS, Jacks T, Rabinowitz JD, White E.

Genes Dev. 2013 Jul 1;27(13):1447-61. doi: 10.1101/gad.219642.113.

3.

Autophagy promotes BrafV600E-driven lung tumorigenesis by preserving mitochondrial metabolism.

Strohecker AM, White E.

Autophagy. 2014 Feb;10(2):384-5. doi: 10.4161/auto.27320. Epub 2013 Dec 17.

PMID:
24362353
4.

Loss of p53 attenuates the contribution of IL-6 deletion on suppressed tumor progression and extended survival in Kras-driven murine lung cancer.

Tan X, Carretero J, Chen Z, Zhang J, Wang Y, Chen J, Li X, Ye H, Tang C, Cheng X, Hou N, Yang X, Wong KK.

PLoS One. 2013 Nov 15;8(11):e80885. doi: 10.1371/journal.pone.0080885. eCollection 2013.

5.

Autophagy sustains mitochondrial glutamine metabolism and growth of BrafV600E-driven lung tumors.

Strohecker AM, Guo JY, Karsli-Uzunbas G, Price SM, Chen GJ, Mathew R, McMahon M, White E.

Cancer Discov. 2013 Nov;3(11):1272-85. doi: 10.1158/2159-8290.CD-13-0397. Epub 2013 Aug 21.

6.

Autophagy is required for mitochondrial function, lipid metabolism, growth, and fate of KRAS(G12D)-driven lung tumors.

Guo JY, White E.

Autophagy. 2013 Oct;9(10):1636-8. doi: 10.4161/auto.26123. Epub 2013 Aug 15. Review.

PMID:
23959381
7.

The p53 Target Gene SIVA Enables Non-Small Cell Lung Cancer Development.

Van Nostrand JL, Brisac A, Mello SS, Jacobs SB, Luong R, Attardi LD.

Cancer Discov. 2015 Jun;5(6):622-35. doi: 10.1158/2159-8290.CD-14-0921. Epub 2015 Mar 26.

8.

The expression of p33(ING1), p53, and autophagy-related gene Beclin1 in patients with non-small cell lung cancer.

Liu J, Lin Y, Yang H, Deng Q, Chen G, He J.

Tumour Biol. 2011 Dec;32(6):1113-21. doi: 10.1007/s13277-011-0211-4. Epub 2011 Jul 22.

PMID:
21779982
9.

p53 status determines the role of autophagy in pancreatic tumour development.

Rosenfeldt MT, O'Prey J, Morton JP, Nixon C, MacKay G, Mrowinska A, Au A, Rai TS, Zheng L, Ridgway R, Adams PD, Anderson KI, Gottlieb E, Sansom OJ, Ryan KM.

Nature. 2013 Dec 12;504(7479):296-300. doi: 10.1038/nature12865. Epub 2013 Dec 4.

PMID:
24305049
10.

Atg7 Overcomes Senescence and Promotes Growth of BrafV600E-Driven Melanoma.

Xie X, Koh JY, Price S, White E, Mehnert JM.

Cancer Discov. 2015 Apr;5(4):410-23. doi: 10.1158/2159-8290.CD-14-1473. Epub 2015 Feb 11.

11.

Notch1 is required for Kras-induced lung adenocarcinoma and controls tumor cell survival via p53.

Licciulli S, Avila JL, Hanlon L, Troutman S, Cesaroni M, Kota S, Keith B, Simon MC, Puré E, Radtke F, Capobianco AJ, Kissil JL.

Cancer Res. 2013 Oct 1;73(19):5974-84. doi: 10.1158/0008-5472.CAN-13-1384. Epub 2013 Aug 13.

12.

Scrib heterozygosity predisposes to lung cancer and cooperates with KRas hyperactivation to accelerate lung cancer progression in vivo.

Elsum IA, Yates LL, Pearson HB, Phesse TJ, Long F, O'Donoghue R, Ernst M, Cullinane C, Humbert PO.

Oncogene. 2014 Nov 27;33(48):5523-33. doi: 10.1038/onc.2013.498. Epub 2013 Nov 25.

PMID:
24276238
13.

Erlotinib-induced autophagy in epidermal growth factor receptor mutated non-small cell lung cancer.

Li YY, Lam SK, Mak JC, Zheng CY, Ho JC.

Lung Cancer. 2013 Sep;81(3):354-61. doi: 10.1016/j.lungcan.2013.05.012. Epub 2013 Jun 13.

PMID:
23769318
14.

MEK1/2 inhibition elicits regression of autochthonous lung tumors induced by KRASG12D or BRAFV600E.

Trejo CL, Juan J, Vicent S, Sweet-Cordero A, McMahon M.

Cancer Res. 2012 Jun 15;72(12):3048-59. doi: 10.1158/0008-5472.CAN-11-3649. Epub 2012 Apr 17.

15.

Macroautophagy is dispensable for growth of KRAS mutant tumors and chloroquine efficacy.

Eng CH, Wang Z, Tkach D, Toral-Barza L, Ugwonali S, Liu S, Fitzgerald SL, George E, Frias E, Cochran N, De Jesus R, McAllister G, Hoffman GR, Bray K, Lemon L, Lucas J, Fantin VR, Abraham RT, Murphy LO, Nyfeler B.

Proc Natl Acad Sci U S A. 2016 Jan 5;113(1):182-7. doi: 10.1073/pnas.1515617113. Epub 2015 Dec 17.

16.

Low frequency of p53 and k-ras codon 12 mutations in non-small cell lung carcinoma (NSCLC) tumors and surgical margins.

Vatan O, Bilaloglu R, Tunca B, Cecener G, Gebitekin C, Egeli U, Yakut T, Urer N.

Tumori. 2007 Sep-Oct;93(5):473-7.

17.
18.

Long non-coding RNA MEG3 inhibits NSCLC cells proliferation and induces apoptosis by affecting p53 expression.

Lu KH, Li W, Liu XH, Sun M, Zhang ML, Wu WQ, Xie WP, Hou YY.

BMC Cancer. 2013 Oct 7;13:461. doi: 10.1186/1471-2407-13-461.

19.

[Expression of surviving gene and its relationship with expression of P53, c-myc, k-ras proteins in non-small-cell lung cancer].

Wang X, Chen S, Zhang Z.

Zhonghua Jie He He Hu Xi Za Zhi. 2001 Jun;24(6):371-4. Chinese.

PMID:
11802993
20.

miRNA-34 prevents cancer initiation and progression in a therapeutically resistant K-ras and p53-induced mouse model of lung adenocarcinoma.

Kasinski AL, Slack FJ.

Cancer Res. 2012 Nov 1;72(21):5576-87. doi: 10.1158/0008-5472.CAN-12-2001. Epub 2012 Sep 10.

Items per page

Supplemental Content

Write to the Help Desk